Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Major Reduction in Axillary Lymph Node Dissections After Neoadjuvant Systemic Therapy for Node-Positive Breast Cancer by combining PET/CT and the MARI Procedure.
van der Noordaa MEM, van Duijnhoven FH, Straver ME, Groen EJ, Stokkel M, Loo CE, Elkhuizen PHM, Russell NS, Vrancken Peeters MTFD. van der Noordaa MEM, et al. Among authors: van duijnhoven fh. Ann Surg Oncol. 2018 Jun;25(6):1512-1520. doi: 10.1245/s10434-018-6404-y. Epub 2018 Mar 6. Ann Surg Oncol. 2018. PMID: 29511992
Internal Mammary Chain Sentinel Nodes in Early-Stage Breast Cancer Patients: Toward Selective Removal.
van Loevezijn AA, Bartels SAL, van Duijnhoven FH, Heemsbergen WD, Bosma SCJ, Elkhuizen PHM, Donswijk ML, Rutgers EJT, Oldenburg HSA, Vrancken Peeters MTFD, van der Ploeg IMC. van Loevezijn AA, et al. Among authors: van duijnhoven fh, van der ploeg imc. Ann Surg Oncol. 2019 Apr;26(4):945-953. doi: 10.1245/s10434-018-7058-5. Epub 2018 Nov 21. Ann Surg Oncol. 2019. PMID: 30465222 Clinical Trial.
Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol.
van Loevezijn AA, van der Noordaa MEM, Stokkel MPM, van Werkhoven ED, Groen EJ, Loo CE, Elkhuizen PHM, Sonke GS, Russell NS, van Duijnhoven FH, Vrancken Peeters MTFD. van Loevezijn AA, et al. Among authors: van duijnhoven fh, van der noordaa mem, van werkhoven ed. Breast Cancer Res Treat. 2022 May;193(1):37-48. doi: 10.1007/s10549-022-06545-z. Epub 2022 Mar 3. Breast Cancer Res Treat. 2022. PMID: 35239072 Free PMC article.
Immediate or delayed oncoplastic surgery after breast conserving surgery at the Netherlands Cancer Institute: a cohort study of 251 cases.
van Loevezijn AA, Geluk CS, van den Berg MJ, van Werkhoven ED, Vrancken Peeters MTFD, van Duijnhoven FH, Hoornweg MJ. van Loevezijn AA, et al. Among authors: van duijnhoven fh, van den berg mj, van werkhoven ed. Breast Cancer Res Treat. 2023 Apr;198(2):295-307. doi: 10.1007/s10549-022-06841-8. Epub 2023 Jan 24. Breast Cancer Res Treat. 2023. PMID: 36690822
De-ESCAlating RadioTherapy in breast cancer patients with pathologic complete response to neoadjuvant systemic therapy: DESCARTES study.
van Hemert AKE, van Olmen JP, Boersma LJ, Maduro JH, Russell NS, Tol J, Engelhardt EG, Rutgers EJT, Vrancken Peeters MTFD, van Duijnhoven FH. van Hemert AKE, et al. Among authors: van olmen jp, van duijnhoven fh. Breast Cancer Res Treat. 2023 May;199(1):81-89. doi: 10.1007/s10549-023-06899-y. Epub 2023 Mar 9. Breast Cancer Res Treat. 2023. PMID: 36892723
Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups.
Pasquier D, Bidaut L, Oprea-Lager DE, deSouza NM, Krug D, Collette L, Kunz W, Belkacemi Y, Bau MG, Caramella C, De Geus-Oei LF, De Caluwé A, Deroose C, Gheysens O, Herrmann K, Kindts I, Kontos M, Kümmel S, Linderholm B, Lopci E, Meattini I, Smeets A, Kaidar-Person O, Poortmans P, Tsoutsou P, Hajjaji N, Russell N, Senkus E, Talbot JN, Umutlu L, Vandecaveye V, Verhoeff JJC, van Oordt WMH, Zacho HD, Cardoso F, Fournier L, Van Duijnhoven F, Lecouvet FE. Pasquier D, et al. Lancet Oncol. 2023 Aug;24(8):e331-e343. doi: 10.1016/S1470-2045(23)00286-3. Lancet Oncol. 2023. PMID: 37541279 Review.
70 results